New research emerged this month shining light on the need for wider use of continuous glucose monitors (CGMs). The study — which was conducted by CCS, a chronic care management company — analyzed data ...

On April 24, the Centers for Medicare and Medicaid Services announced plans to overhaul the Meaningful Use program by turning to a focus on interoperability. Thus, it only makes sense that the agency ...

More than 400 rural hospitals across the country are at risk of closure, battling a mix of reimbursement issues, workforce struggles and policy decisions that have left safety net providers ...

The FDA turned down an Intercept Pharmaceuticals drug application for the fatty liver disease NASH, a decision that comes nearly three years after the regulator first rejected the molecule. The agency ...

For healthcare leaders evaluating procurement options or clinicians recommending at-home care, selecting the right gel pack supplier requires careful evaluation of durability, temperature retention, ...

This roundup is published monthly. It is meant to highlight some of healthcare’s recent hiring news and is not intended to be comprehensive. If you have news about an executive appointment, ...

Eli Lilly’s engineered peptide drugs Mounjaro and Zepbound are once-weekly injectable products, formulations that are expensive to manufacture and burdensome to patients who dislike needles. Lilly ...

Healthcare leaders must resist using AI as a substitute for staffing. Instead, invest in workforce optimization technology that empowers nurses, creates flexible pathways, and addresses the systemic ...

Much of President Donald Trump’s Tuesday State of the Union address centered on immigration and tariffs. However, he also addressed several healthcare issues, including a renewed criticism of the ...

Otsuka Pharmaceutical is broadening its scope in rare disease, striking a deal to acquire Jnana Therapeutics and its lead drug candidate, a small molecule on track for pivotal testing in a metabolic ...

Positive Development, a developmental therapy provider for children with autism, announced Wednesday that it raised $51.5 million in Series C funding. The McLean, Virginia-based company’s model is ...

Johnson & Johnson is boosting its immunology and inflammation drug pipeline with the acquisition of Proteologix, a startup whose most advanced program is ready for Phase 1 testing in asthma and atopic ...